Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Other |
Number of participants who died including all-cause, cardiovascular, and non-cardiovascular death |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants who experienced a Stroke including disabling and non-disabling |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with Myocardial infarction (MI): periprocedural (=72 hours post index procedure) and spontaneous (>72 hours post index procedure) |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with Bleeding: life-threatening (or disabling) and major |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with Acute kidney injury based on the AKIN System Stage 3 (including renal replacement therapy) or Stage 2 |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
=7 days post index procedure |
|
Other |
Number of participants with Major vascular complication |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with Repeat procedure for valve-related dysfunction (surgical or interventional therapy) |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with Hospitalization for valve-related symptoms or worsening congestive heart failure (New York Heart Association [NYHA] class III or IV) |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with New permanent pacemaker implantation (PPI) resulting from new or worsened conduction disturbances |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with New onset of atrial fibrillation or atrial flutter |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with Coronary obstruction: periprocedural |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
=72 hours post index procedure |
|
Other |
Number of participants with Ventricular septal perforation: periprocedural |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
=72 hours post index procedure |
|
Other |
Number of participants with Mitral apparatus damage: periprocedural |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
=72 hours post index procedure |
|
Other |
Number of participants with Cardiac tamponade: periprocedural |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
=72 hours post index procedure |
|
Other |
Number of participants with Valve migration |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with Valve embolization |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with Ectopic valve deployment |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with Transcatheter aortic valve (TAV)-in-TAV deployment |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with Prosthetic aortic valve thrombosis |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with Prosthetic aortic valve endocarditis |
Adjudicated by an independent Clinical Events Committee (CEC) based on VARC 2 definitions |
Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1 year |
|
Other |
Number of participants with successful vascular access, delivery and deployment of the study valve, and successful retrieval of the delivery system (site reported assessment) |
Device Performance endpoint, as measured by site reported data |
Participants will be followed for the duration of their procedure, an expected average of 1 day (peri- and post-procedure) |
|
Other |
Grade of aortic regurgitation/paravalvular leak (PVL) (echocardiographic assessment) |
Device Performance endpoint, as assessed by Echocardiographic Core Laboratory |
Participants will be followed for the duration of their procedure, an expected average of 1 day (peri- and post-procedure) |
|
Other |
Prosthetic aortic valve performance: Effective Orifice Area (EOA) |
Effective Orifice Area (EOA), as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory |
Discharge or 7 days post index procedure (whichever comes first), 30 days, 6 months, and 1 year |
|
Other |
Prosthetic aortic valve performance: Mean Aortic Gradient |
Mean aortic gradient as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory |
Discharge or 7 days post index procedure (whichever comes first), 30 days, 6 months, and 1 year |
|
Other |
Prosthetic aortic valve performance: Peak Aortic Gradient |
Peak Aortic Gradient as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory |
Discharge or 7 days post index procedure (whichever comes first), 30 days, 6 months, and 1 year |
|
Other |
Prosthetic aortic valve performance: Peak Aortic Velocity |
Peak Aortic Velocity as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory |
Discharge or 7 days post index procedure (whichever comes first), 30 days, 6 months, and 1 year |
|
Other |
Prosthetic aortic valve performance: Grade of Aortic Regurgitation/PVL |
Grade of Aortic Regurgitation/PVL as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory |
Discharge or 7 days post index procedure (whichever comes first), 30 days, 6 months, and 1 year |
|
Other |
Number of participants with a New York Heart Association (NYHA) Functional Status classification of Class I, II, III or IV |
Evaluated by New York Heart Association (NYHA) classification |
Discharge or 7 days post index procedure (whichever comes first), 30 days, 6 months, and 1 year |
|
Other |
Neurological status: Participant score for National Institutes of Health Stroke Scale (NIHSS) assessment |
Evaluated by National Institutes of Health Stroke Scale (NIHSS) - Minimum: 0 (No stroke symptoms); Max: 21-42 (Severe stroke) |
Discharge or 7 days post index procedure (whichever comes first) and 1 year and when is stroke is suspected |
|
Other |
Neurological status: Participant score for Modified Rankin Scale (mRS) Assessment |
Evaluated by Modified Rankin Scale (mRS) - min: 0 (The patient has no residual symptoms); max: 6 (The patient has expired) |
Discharge or 7 days post index procedure (whichever comes first), 30 days, 6 months, and 1 year, and when is stroke is suspected (and 90 days post stroke) |
|
Other |
Neurological status: Number of participants with a confirmed stroke per Neurological physical exam assessment |
Evaluated per neurological physical exam in all subjects where stroke is suspected |
Participants will be followed for the duration of the trial, through 1 year |
|
Primary |
Number of participants with Device Success |
Absence of procedural mortality, AND Correct positioning of a single valve into the proper anatomical location, AND Intended performance of the study device (indexed effective orifice area [iEOA] >0.85 cm2/m2 for BMI <30 kg/m2 and iEOA >0.70 cm2/m2 for BMI =30 kg/m2 plus either a mean aortic valve gradient <20 mmHg or a peak velocity <3m/sec, and no moderate or severe prosthetic valve aortic regurgitation) as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory. |
Through discharge or 7 days post procedure |
|
Primary |
Number of participants who died or experienced a stroke |
Composite of all-cause mortality and all stroke A Clinical Events Committee (CEC), independent group of physician experts will be used to evaluate all reported cases of death and stroke to determine whether they met the specific protocol definition of the event. |
Through 30 Days post procedure |
|